Welcome to our dedicated page for Inogen SEC filings (Ticker: INGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking FDA discussions, reimbursement risks, and rental-unit metrics in Inogen’s disclosures can feel like untangling medical jargon. Each 10-K details device-quality systems and portable oxygen concentrator trends, while 10-Qs update segment margins and inventory swings. Add Form 4 insider trades and the puzzle grows. If you have ever searched “Inogen SEC filings explained simply,” you already know the challenge.
Stock Titan solves it. Our AI digests every Inogen annual report 10-K simplified edition, flags changes in reimbursement language, and summarizes risk factors in plain English. Need the latest “Inogen quarterly earnings report 10-Q filing” or an 8-K about a product recall? Real-time EDGAR feeds alert you the moment it posts. You can even follow “Inogen insider trading Form 4 transactions” with instant push updates, turning hours of manual review into minutes of insight.
Here’s what you’ll uncover:
- Bulletproof AI synopses that clarify revenue drivers and cash-flow shifts.
- “Inogen executive stock transactions Form 4” dashboards showing buying and selling patterns.
- Side-by-side “Inogen earnings report filing analysis” for quarter-over-quarter unit shipments.
- Clear flags when an “Inogen proxy statement executive compensation” plan ties bonuses to new concentrator launches.
- “Inogen 8-K material events explained” so you grasp recall notices or leadership changes fast.
Whether you’re monitoring “understanding Inogen SEC documents with AI” before an investment decision or verifying “Inogen Form 4 insider transactions real-time” ahead of a trade, Stock Titan equips you with comprehensive filing coverage, expert context, and AI-powered clarity—all updated the second Inogen files with the SEC.
Michael J. Bourque, EVP, CFO & Treasurer of Inogen Inc. (INGN), acquired 1,500 shares of the company's common stock on 09/01/2025 at a price of $7.99 per share under the 2014 Employee Stock Purchase Plan. After the purchase, Mr. Bourque directly beneficially owned 49,146 shares. The Form 4 was executed by Mary Wright as Attorney-in-Fact and dated 09/03/2025. The filing indicates the transaction was reported under Section 16 and that the purchase was made pursuant to a company plan; no derivatives, dispositions, or additional transactions are reported on this form.
Kevin P. Smith, Executive Vice President, Business Development, General Counsel and Secretary of Inogen Inc. (INGN), reported transactions on September 1, 2025 that changed his beneficial ownership. He purchased 1,500 shares under the companys 2014 Employee Stock Purchase Plan at $7.99 per share and received 18,135 restricted stock units (each representing one share) that vested in part on that date. To satisfy tax withholding on a portion of the vested awards, 8,043 shares were withheld. After these transactions Mr. Smith beneficially owns 36,271 shares.
The restricted stock units vest in three equal annual tranches, with one-third vested on September 1, 2025 and the remainder subject to continued service on the same annual date.
Kevin Raymond Smith, CEO, President and a director of Inogen Inc (INGN), reported acquiring 1,500 shares of Common Stock on 09/01/2025 at a purchase price of $7.99 per share under the company’s 2014 Employee Stock Purchase Plan. After the purchase, Mr. Smith beneficially owns 71,774 shares directly. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/03/2025. The filing indicates the transaction was made pursuant to a written plan intended to satisfy Rule 10b5-1(c)'s affirmative defense.
Inogen, Inc. reported consolidated second-quarter revenue of $92.3 million, up 4.0% year-over-year, driven by higher sales revenue of $79.2 million as unit shipments rose to ~49,000 systems versus ~41,300 a year earlier. Rental revenue declined 8.6% to $13.1 million, reflecting a shift toward lower private-payor reimbursement.
Gross margin narrowed to 44.8% from 48.1%, attributed to customer/channel mix and higher materials costs including semiconductor premiums. The company reported a net loss of $4.152 million in Q2 and a six-month loss of $10.326 million, while operating activities used $12.44 million of cash year-to-date. Liquidity remained solid with cash and cash equivalents of $103.7 million and total cash, cash equivalents and restricted cash of $104.96 million.
Corporate developments included a $27.21 million private placement with Yuwell, a Strategic Collaboration Agreement with Yuwell to broaden product distribution and accelerate Chinese market entry, and completion of earnout payments related to the Physio-Assist acquisition. Management is evaluating recent U.S. tax legislation and continues to record a valuation allowance on deferred tax assets.
FAQ
What is the current stock price of Inogen (INGN)?
What is the market cap of Inogen (INGN)?
